Biotech AssistantIndependent biopharma research
BIOTECH ASSISTANT / FIELD NOTES

Asymchem reports nine-month revenue growth of 16.52%

Regulatory / securities filing · 凯莱英 / 巨潮资讯 CNinfo

Source published: · Event / reporting date: 2026-09-30

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What changed

Asymchem reported consolidated revenue of RMB5.395 billion, up 16.52%, and attributable net income of RMB852.2 million for the nine months ended September 30, 2026. Attributable net income grew 6.49%, trailing the increase in revenue over the same nine-month period. The quarterly filing is unaudited and covers the year-to-date period.

Why it may matter

The gap between revenue and profit growth deserves monitoring; stronger CDMO sales alone do not demonstrate improved profitability.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

China-listed CRO/CDMO

Related updates

Fresenius

Fresenius gains development options on up to 37 WuXi Biologics biosimilar candidates

Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.

China-listed CRO/CDMOAsk AI ↗
百奥赛图 / 巨潮资讯 CNinfo

Biocytogen reports nine-month revenue growth of 49.09%

Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.

China-listed CRO/CDMOAsk AI ↗
药石科技 / 巨潮资讯 CNinfo

PharmaBlock Sciences reports nine-month revenue growth of 15.16%

PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.

China-listed CRO/CDMOAsk AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗